Reviews
Vol. 4 No. 2 (2025)
Hemostasis and the kidney: an unforeseen initial opportunity to create a small research group that grew into an institute
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 30 June 2025
324
Views
84
Downloads
Authors
This is the story of how, in the mid-1970s, a small group of young doctors and scientists in Bergamo began studying hemostasis and thrombosis in kidney diseases in collaboration with hematology researchers at Mario Negri Institute in Milan. At a small laboratory that was set up in the Nephrology and Dialysis division of Bergamo Hospital, their collaborative earlier research focused on platelet-vessel wall interactions, prostaglandins and bleeding in uremia, prostacyclin and prostacyclin-stimulating plasma factors in pre-eclampsia and thrombotic microangiopathies, and platelet hyperaggregability in nephrotic syndrome. As the group grew, so did the need to address patients’ nephrological problems through more efficient laboratory research. This led to the foundation of the Mario Negri Bergamo Institute in 1984. Since then, their research work has expanded to include mechanisms of proteinuria and disease progression, organ transplantation and rejection, tolerance, autoimmune disease, glomerulonephritis, molecular biology, and more. In 1992, the Aldo and Cele Daccò Clinical Research Center for Rare Disease was established as an integral part of the Institute.
Downloads
Download data is not yet available.
Citations
1. Remuzzi G, Livio M, Roncaglioni MC, et al. Bleeding in renal failure: is von Willebrand factor implicated? Br Med J 1977;2:359-61. DOI: https://doi.org/10.1136/bmj.2.6083.359
2. Remuzzi G, Cavenaghi AE, Mecca G, et al. Prostacyclin-like activity and bleeding in renal failure. Lancet 1977;2:1195-7. DOI: https://doi.org/10.1016/S0140-6736(77)90437-8
3. Remuzzi G, Cavenaghi AE, Mecca G, et al. Prostacyclin (PGI2) and bleeding time in uremic patients. Thromb Res 1977;11:919-20. DOI: https://doi.org/10.1016/0049-3848(77)90122-0
4. Remuzzi G, Marchesi D, Livio M, et al. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978;13:1007-15. DOI: https://doi.org/10.1016/0049-3848(78)90229-3
5. Remuzzi G, Cavenaghi AE, Mecca G, et al. Human renal cortex generates prostacyclin-like activity. Thromb Res 1978;12:363-6. DOI: https://doi.org/10.1016/0049-3848(78)90307-9
6. Remuzzi G, Livio M, Marchiaro G, et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978;22:347-53. DOI: https://doi.org/10.1159/000181474
7. Remuzzi G, Bertani T, Mecca G, et al. Factor VIII--related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times. Br Med J 1978;1:70-2. DOI: https://doi.org/10.1136/bmj.1.6105.70
8. Remuzzi G, Livio M, Cavenaghi AE, et al. Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thromb Res 1978;13:531-6. DOI: https://doi.org/10.1016/0049-3848(78)90138-X
9. Remuzzi G, Marchesi D, Cavenaghi AE, et al. Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2). Clin Nephrol 1979;12:127-31.
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5. DOI: https://doi.org/10.1038/263663a0
11. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977;1:18-20. DOI: https://doi.org/10.1016/S0140-6736(77)91655-5
12. Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 1976;88:167-72.
13. MacIntyre DE, Pearson JD, Gordon JL. Localisation and stimulation of prostacyclin production in vascular cells. Nature 1978;271:549-51. DOI: https://doi.org/10.1038/271549a0
14. Defreyn G, Dauden MV, Machin SJ, Vermylen J. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 1980;19:695-9. DOI: https://doi.org/10.1016/0049-3848(80)90041-9
15. de Castellarnau C, Vila L, Sancho MJ, et al. Lupus anticoagulant, recurrent abortion, and prostacyclin production by cultured smooth muscle cells. Lancet 1983;2:1137-8. DOI: https://doi.org/10.1016/S0140-6736(83)90646-3
16. Deckmyn H, Zoja C, Arnout J, et al. Partial isolation and function of the prostacyclin regulating plasma factor. Clin Sci (Lond) 1985;69:383-93. DOI: https://doi.org/10.1042/cs0690383
17. Remuzzi G, Benigni A, Dodesini P, et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 1983;71:762-8. DOI: https://doi.org/10.1172/JCI110824
18. Remuzzi G, Misiani R, Muratore D, et al. Prostacyclin and human foetal circulation. Prostaglandins 1979;18:341-8. DOI: https://doi.org/10.1016/S0090-6980(79)80052-0
19. Remuzzi G, Marchesi D, Mecca G, et al. Reduction of fetal vascular prostacyclin activity in pre-eclampsia. Lancet 1980;2:310. DOI: https://doi.org/10.1016/S0140-6736(80)90249-4
20. Remuzzi G, Marchesi D, Zoja C, et al. Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins 1980;20:105-10. DOI: https://doi.org/10.1016/0090-6980(80)90010-6
21. Remuzzi G, Zoja C, Marchesi D, et al. Plasmatic regulation of vascular prostacyclin in pregnancy. Br Med J (Clin Res Ed) 1981;282:512-4. DOI: https://doi.org/10.1136/bmj.282.6263.512
22. Remuzzi G, Mecca G, Marchesi D, et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979;16:345-54. DOI: https://doi.org/10.1016/0049-3848(79)90082-3
23. Schieppati A, Dodesini P, Benigni A, et al. The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int 1984;25:671-6. DOI: https://doi.org/10.1038/ki.1984.72
24. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46. DOI: https://doi.org/10.1046/j.1523-1755.2001.060003831.x
25. Zoja C, Morigi M, Remuzzi G. The role of the endothelium in hemolytic uremic syndrome. J Nephrol 2001;14:S58-62.
26. Remuzzi G, Imberti L, de Gaetano G. Prostacyclin deficiency in thrombotic microangiopathy. Lancet 1981;2:1422-3. DOI: https://doi.org/10.1016/S0140-6736(81)92837-3
27. Remuzzi G, Misiani R, Marchesi D, et al. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 1978;2:871-2. DOI: https://doi.org/10.1016/S0140-6736(78)91573-8
28. Remuzzi G, Misiani R, Mecca G, et al. Thrombotic thrombocytopenic purpura--a deficiency of plasma factors regulating platelet-vessel-wall interaction? N Engl J Med 1978;299:311. DOI: https://doi.org/10.1056/NEJM197808102990616
29. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-87. DOI: https://doi.org/10.1056/NEJMra0902814
30. Breno M, Noris M, Rubis N, et al. ORIGIN study group. A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals. IScience 2023;26:107629. DOI: https://doi.org/10.1016/j.isci.2023.107629
31. Cerletti C, Tamburrelli C, Izzi B, et al. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012;129:263-6. DOI: https://doi.org/10.1016/j.thromres.2011.10.010
How to Cite
1.
Zoja C, Benigni A, Remuzzi G. Hemostasis and the kidney: an unforeseen initial opportunity to create a small research group that grew into an institute. Bleeding Thromb Vascul Biol [Internet]. 2025 Jun. 30 [cited 2025 Nov. 7];4(2). Available from: https://www.btvb.org/btvb/article/view/190
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- CO38 | Management of pregnancy, delivery, and postpartum in Italian carriers and women with hemophilia A and B , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Luca D'Ambrosio, Maurizio Forte, Giacomo Frati, Sebastiano Sciarretta, Role of platelet autophagy in cardiovascular diseases , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- CO43 | Early platelet dysfunction in sepsis: an ICU pilot study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Fabio Tumminello, Silvia Cardi, Corrado Lodigiani, Maria Elisa Mancuso, Antithrombotic therapy in idiopathic infertility , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- CO10 | Multidimensional risk assessment of venous thromboembolism (risk): an observational study comparing the Padua prediction score, Barthel index, and quality of life in hospitalized patients , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo, Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- CO02 | Hepatic fibrosis as predictor of cancer-associated thrombosis in patients with intrahepatic cholangiocarcinoma , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro, The von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
